Potentiating intratumoral therapy with immune checkpoint inhibitors: shifting the paradigm of multimodality therapeutics
Immune checkpoint inhibitors (ICIs) have revolutionized oncology, yielding remarkable and durable responses in various cancers. However, a significant proportion of patients develop resistance to ICIs. The tumor microenvironment plays a critical role in immunotherapy resistance, characterized by imm...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | Immuno-Oncology and Technology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S259001882400337X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832573053987454976 |
|---|---|
| author | B.E. Nelson A. Naing S. Fu R.A. Sheth R. Murthy S. Piha-Paul |
| author_facet | B.E. Nelson A. Naing S. Fu R.A. Sheth R. Murthy S. Piha-Paul |
| author_sort | B.E. Nelson |
| collection | DOAJ |
| description | Immune checkpoint inhibitors (ICIs) have revolutionized oncology, yielding remarkable and durable responses in various cancers. However, a significant proportion of patients develop resistance to ICIs. The tumor microenvironment plays a critical role in immunotherapy resistance, characterized by immune cell composition, regulatory factors, and tumor mutational burden. Intratumoral immunotherapy, involving direct injection of immune-activating agents into tumors, holds promise for converting immunologically ‘cold’ tumors into responsive ‘hot’ tumors. This review explores the rationale for combining intratumoral therapies (ITs) with ICIs, highlighting their complementary mechanisms of action and clinical effects. Notable IT approaches include oncolytic viruses, toll-like receptor agonists, and stimulator of interferon gene agonists with ICIs. Overall, combining ITs with ICIs offers a rational strategy to potentiate antitumor immune response and overcome resistance. Further research is needed to optimize the combination strategies, identify biomarkers of response, and establish the safety and efficacy of these novel therapeutic approaches. |
| format | Article |
| id | doaj-art-0c370c87d3f54a67a0715c2c6910546d |
| institution | Kabale University |
| issn | 2590-0188 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Immuno-Oncology and Technology |
| spelling | doaj-art-0c370c87d3f54a67a0715c2c6910546d2025-02-02T05:29:12ZengElsevierImmuno-Oncology and Technology2590-01882025-03-0125101040Potentiating intratumoral therapy with immune checkpoint inhibitors: shifting the paradigm of multimodality therapeuticsB.E. Nelson0A. Naing1S. Fu2R.A. Sheth3R. Murthy4S. Piha-Paul5Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, USADepartment of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, USADepartment of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, USADepartment of Interventional Radiology, University of Texas MD Anderson Cancer Center, Houston, USADepartment of Interventional Radiology, University of Texas MD Anderson Cancer Center, Houston, USADepartment of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, USA; Correspondence to: Prof. Sarina Piha-Paul, Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Tel: +713-563-1055Immune checkpoint inhibitors (ICIs) have revolutionized oncology, yielding remarkable and durable responses in various cancers. However, a significant proportion of patients develop resistance to ICIs. The tumor microenvironment plays a critical role in immunotherapy resistance, characterized by immune cell composition, regulatory factors, and tumor mutational burden. Intratumoral immunotherapy, involving direct injection of immune-activating agents into tumors, holds promise for converting immunologically ‘cold’ tumors into responsive ‘hot’ tumors. This review explores the rationale for combining intratumoral therapies (ITs) with ICIs, highlighting their complementary mechanisms of action and clinical effects. Notable IT approaches include oncolytic viruses, toll-like receptor agonists, and stimulator of interferon gene agonists with ICIs. Overall, combining ITs with ICIs offers a rational strategy to potentiate antitumor immune response and overcome resistance. Further research is needed to optimize the combination strategies, identify biomarkers of response, and establish the safety and efficacy of these novel therapeutic approaches.http://www.sciencedirect.com/science/article/pii/S259001882400337Xintratumoral therapyimmune checkpoint inhibitors |
| spellingShingle | B.E. Nelson A. Naing S. Fu R.A. Sheth R. Murthy S. Piha-Paul Potentiating intratumoral therapy with immune checkpoint inhibitors: shifting the paradigm of multimodality therapeutics Immuno-Oncology and Technology intratumoral therapy immune checkpoint inhibitors |
| title | Potentiating intratumoral therapy with immune checkpoint inhibitors: shifting the paradigm of multimodality therapeutics |
| title_full | Potentiating intratumoral therapy with immune checkpoint inhibitors: shifting the paradigm of multimodality therapeutics |
| title_fullStr | Potentiating intratumoral therapy with immune checkpoint inhibitors: shifting the paradigm of multimodality therapeutics |
| title_full_unstemmed | Potentiating intratumoral therapy with immune checkpoint inhibitors: shifting the paradigm of multimodality therapeutics |
| title_short | Potentiating intratumoral therapy with immune checkpoint inhibitors: shifting the paradigm of multimodality therapeutics |
| title_sort | potentiating intratumoral therapy with immune checkpoint inhibitors shifting the paradigm of multimodality therapeutics |
| topic | intratumoral therapy immune checkpoint inhibitors |
| url | http://www.sciencedirect.com/science/article/pii/S259001882400337X |
| work_keys_str_mv | AT benelson potentiatingintratumoraltherapywithimmunecheckpointinhibitorsshiftingtheparadigmofmultimodalitytherapeutics AT anaing potentiatingintratumoraltherapywithimmunecheckpointinhibitorsshiftingtheparadigmofmultimodalitytherapeutics AT sfu potentiatingintratumoraltherapywithimmunecheckpointinhibitorsshiftingtheparadigmofmultimodalitytherapeutics AT rasheth potentiatingintratumoraltherapywithimmunecheckpointinhibitorsshiftingtheparadigmofmultimodalitytherapeutics AT rmurthy potentiatingintratumoraltherapywithimmunecheckpointinhibitorsshiftingtheparadigmofmultimodalitytherapeutics AT spihapaul potentiatingintratumoraltherapywithimmunecheckpointinhibitorsshiftingtheparadigmofmultimodalitytherapeutics |